Max Rothwell graduated with a first-class M.Sci. degree in Neuroscience at the University of Nottingham in 2016. During his undergraduate studies, Max spent his third year working as a research student at Eli Lilly & Company (Lilly UK), where his research project involved both behavioural and electrophysiological experiments designed to elucidate pharmacodynamic biomarkers of drug action.
Max is currently pursuing his D.Phil. at the University of Oxford. His thesis research in the Sharott Group is focused on investigating closed-loop adaptive Deep Brain Stimulation (aDBS) approaches for the treatment of Parkinsonism. Such strategies aim to improve upon current DBS therapies by selectively targeting ongoing pathological oscillations within the neuronal circuits of the basal ganglia.